Provided by Tiger Fintech (Singapore) Pte. Ltd.

Soleno Therapeutics

69.98
+0.05000.07%
Post-market: 66.00-3.9800-5.69%19:55 EDT
Volume:1.24M
Turnover:85.92M
Market Cap:3.21B
PE:-15.99
High:70.51
Open:69.96
Low:68.34
Close:69.93
Loading ...

BUZZ-Soleno falls after FDA rejects peer Applied's genetic disease drug

Reuters
·
30 Nov 2024

Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference

GlobeNewswire
·
27 Nov 2024

Soleno Tumbles 17% as FDA Extends Review Timeline for Prader-Willi Treatment

GuruFocus.com
·
26 Nov 2024

Soleno Therapeutics Shares Down 2.9% After Co Announces US FDA Extension of Review Period for Genetic Disorder Treatment

THOMSON REUTERS
·
26 Nov 2024

BUZZ-Soleno Therapeutics falls as FDA extends review of genetic disorder drug

Reuters
·
26 Nov 2024

Soleno Therapeutics Says FDA Extends DCCR NDA Review Citing 'Major Amendment'

MT Newswires Live
·
26 Nov 2024

BRIEF-Soleno Therapeutics Announces FDA Extension Of Review Period For DCCR

Reuters
·
26 Nov 2024

Soleno Therapeutics Shares Slide 13% Premarket After Co Announces US FDA Extension of Review Period for Genetic Disorder Treatment

THOMSON REUTERS
·
26 Nov 2024

Soleno Therapeutics announces U.S.. FDA to ended review period for NDA

TIPRANKS
·
26 Nov 2024

Soleno Therapeutics Inc - New Pdufa Target Action Date Set for March 27, 2025

THOMSON REUTERS
·
26 Nov 2024

Soleno Therapeutics Announces FDA Extension of Review Period for Dccr (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome

THOMSON REUTERS
·
26 Nov 2024

Soleno Therapeutics Inc - FDA Did Not Cite Safety, Efficacy or Manufacturing Concerns

THOMSON REUTERS
·
26 Nov 2024

Soleno: FDA Determined That Responses to Recent Information Requests Constituted a Major Amendment to Nda for Dccr Extended-Release Tablets

THOMSON REUTERS
·
26 Nov 2024

Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome

GlobeNewswire
·
26 Nov 2024

Here are 4 biotech stocks that could get a boost from Trump's new regulatory climate

Dow Jones
·
23 Nov 2024

Here are 4 biotech stocks that could get a boost from Trump's new regulatory climate

Dow Jones
·
20 Nov 2024

Biotech-stock investing has one tough test for success - and it's about to get easier

Dow Jones
·
18 Nov 2024

Soleno Therapeutics Announces Oral Presentations Featuring Diazoxide Choline Extended-Release (Dccr) Tablets in Prader-Willi Syndrome at Espe 2024

THOMSON REUTERS
·
15 Nov 2024

Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024

GlobeNewswire
·
15 Nov 2024

Here's Why We're Not At All Concerned With Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Situation

Simply Wall St.
·
12 Nov 2024